BioInvent is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs. Its F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates.
In 2010, after a successful investment period from 1997 to 2010, Industrifonden exited its investment in BioInvent through a block sale on the stock exchange.